|
 |
| home > pmps > summer 2003 > cold chain: risk, regulatory compliance and operational performance |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Risk Assessment
Risk assessment is, at best, an honest attempt to find a rational basis for decisions by analysing the available scientific evidence. In theory it is still an attractive ideal - to make rational decisions based on scientific evidence - because in principle it should allow diverse parties to agree on what needs to be done. However, years of actual practice have badly tarnished the ideal of risk assessment.
In the first place, the necessary data are not always available, even today. In the second place, traditional toxicological assumptions do not always hold up under scrutiny. There is no agreement on which tests to use to determine whether someone's immune system has been damaged. There is no agreement on which tests should be used to assess damage to the nervous system. There is no agreement - and there may never be - on ways to test for genetic damage.
Without agreement on test methods, people cannot agree on which data to include in a risk assessment. Under these circumstances, different risk assessors will select the data that they believe is relevant and they will usually reach different conclusions - often vastly different conclusions. Risk assessment is not a science, it is an art, combining data gathered by scientific methods with a large dose of judgment. Judgment is not reproducible from laboratory to laboratory so different risk assessors reach different conclusions.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Sean Flanagan, Commercial Director at Kryotrans Ltd, and Adrian Shaw, Partner at Ikon Associates
Sean Flanagan is the Commercial Director at Kryotrans Ltd. A qualified accountant, Sean has considerable financial and operational experience with a range of large and small organisations, such as United Technologies Corporation and PROTX Ltd, an Internet start-up company. He is one of three directors at Kryotrans Ltd. He is responsible for marketing, finance, sales and administration and has also developed a number of strategic partnering relationships.
Adrian Shaw is a Partner at Ikon Associates, Marketing Consultants. Having trained in accountancy with Coopers and Lybrand, Adrian has spent the last 15 years working in the PR and marketing services world. He has previously worked as a Director for Gavin Anderson & Co, a PR consultancy, before moving on to Burston Marsteller, where he was a Managing Director responsible for financial and corporate communications work across Europe. He now runs his own corporate brand and marketing services consultancy.
|
|
|
Adrian Shaw |
|
|
|
|
|
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
BASi Opens New Office in Europe
12th November 2008
More info >> |
|
|
